{"product_id":"takara-bio-pestle-analysis","title":"Takara Bio PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Competitive Advantage Starts with This Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how political shifts, biotech funding trends, and rapid gene-editing advances are shaping Takara Bio’s strategic horizon—our PESTLE distills these external forces into clear, actionable insights. Perfect for investors and strategists, the full report reveals regulatory risks, market opportunities, and technological catalysts you can act on today. Purchase the complete PESTLE for an instant, editable briefing that powers smarter decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Trade Relations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOngoing US-China trade tensions disrupt Takara Bio’s supply chain and distribution across North America and Asia, where the company reported roughly 45% of FY2024 revenue; tariffs and logistics delays raised COGS by an estimated 3–5% in 2024. Export controls on genetic-sequencing and biotech reagents—tightened since 2023—threaten market access and could add compliance costs equal to 0.5–1% of revenue. Active diplomatic navigation is critical to protect Takara’s market share and maintain FY2024 regional sales momentum. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Life Science Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePublic funding in genomics and regenerative medicine drives Takara Bio's reagent and instrument sales; global public biotech R\u0026amp;D spending reached about $120 billion in 2024, with Japan allocating ¥1.5 trillion to science and technology in FY2024, supporting academic purchases. Shifts in national budgets—Japan's R\u0026amp;D funding rose 2.8% in 2024 while some EU countries cut research spending—can create revenue volatility from universities. Stable political commitment to biotech innovation is crucial for Takara Bio's long-term growth strategy. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegenerative Medicine Policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe Japanese government’s 2014 Regenerative Medicine Promotion Act and expanded 2024 budget—¥34.2 billion for regenerative medicine R\u0026amp;D—create a supportive framework that gives Takara Bio a domestic competitive edge in cell and gene therapy CDMO services.\u003c\/p\u003e\n\u003cp\u003eRecent initiatives to fast-track gene therapy approvals, cutting review times by up to 30% in pilot programs, can accelerate Takara Bio’s commercialization timeline and revenue recognition.\u003c\/p\u003e\n\u003cp\u003eHowever, electoral shifts could reprioritize funding; a 1% GDP reallocation would materially affect grant flows and market access dynamics for specialized regulatory pathways.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Infrastructure Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cppolitical decisions to modernize healthcare and adopt personalized medicine drive demand for takara bio diagnostics global genomics market reached usd in growing yoy supporting higher sales of pcr kits.\u003e\n\u003cpincreased political focus on pandemic preparedness sustains pcr and ngs demand reported investments of usd in surveillance benefiting suppliers like takara bio.\u003e\n\u003cp\u003eNational bio-manufacturing self-sufficiency strategies (e.g., Japan's 2024 biotech subsidies ~JPY 120B) create opportunities for local production partnerships and contract manufacturing revenues.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGenomics market USD 28.6B (2024), ~12% YoY growth\u003c\/li\u003e\n\u003cli\u003eWHO surveillance funding USD 5.2B (2024)\u003c\/li\u003e\n\u003cli\u003eJapan biotech subsidies ~JPY 120B (2024) — boosts local manufacturing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pincreased\u003e\u003c\/ppolitical\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eData Sovereignty and Bioethics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolitical debates over genetic data handling and gene-editing ethics shape regulatory regimes; globally, 35+ countries had data localization laws by 2024, affecting cross-border genomic transfers for firms like Takara Bio.\u003c\/p\u003e\n\u003cp\u003eGovernments' tightening—EU GDPR fines up to €20M\/4% turnover and India's proposed data rules—increase compliance costs; Takara Bio must adapt policies across its 10+ international labs.\u003c\/p\u003e\n\u003cp\u003eAdhering to shifting political stances on bioethics is required to retain social license and avoid reputational and market access losses in key markets representing over 40% of global biotech revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e35+ countries with data localization by 2024\u003c\/li\u003e\n\u003cli\u003eEU fines up to €20M\/4% global turnover\u003c\/li\u003e\n\u003cli\u003e10+ international Takara Bio labs affected\u003c\/li\u003e\n\u003cli\u003eKey markets \u0026gt;40% of biotech revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitics, public R\u0026amp;D and regulation reshape genomics: market $28.6B, rising costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGeopolitical tensions (US-China) raised FY2024 COGS ~3–5% and risk export-control costs 0.5–1% of revenue; public R\u0026amp;D spending (global $120B; Japan ¥1.5T FY2024) supports reagent sales; Japan’s ¥34.2B regenerative budget and faster gene-therapy approvals (−30% review times) boost CDMO revenue; 35+ data-localization laws and GDPR fines (up to €20M\/4% turnover) increase compliance costs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenomics market\u003c\/td\u003e\n\u003ctd\u003eUSD 28.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal public biotech R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eUSD 120B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJapan S\u0026amp;T budget\u003c\/td\u003e\n\u003ctd\u003e¥1.5T\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJapan regenerative R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e¥34.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWHO surveillance\u003c\/td\u003e\n\u003ctd\u003eUSD 5.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how Political, Economic, Social, Technological, Environmental, and Legal forces uniquely impact Takara Bio, pairing each dimension with data-driven trends and region-specific examples to highlight strategic risks and opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise, visually segmented PESTLE summary of Takara Bio for quick reference in meetings or presentations, enabling easy sharing and alignment across teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Exchange Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs a Japan-based firm with ~45% of FY2024 revenue from overseas, Takara Bio is exposed to JPY\/USD and JPY\/EUR swings; the Yen's 15% depreciation vs. USD since 2021 boosted repatriated sales but risks pricing competitiveness abroad if it rebounds.\u003c\/p\u003e\n\u003cp\u003eIn FY2024 the company reported foreign exchange gains of ¥1.8 billion, highlighting earnings volatility tied to currency moves.\u003c\/p\u003e\n\u003cp\u003eRobust hedging—forward contracts and options covering major currency flows—is essential to stabilize margins amid 2024–25 macro uncertainty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal R\u0026amp;D Expenditure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe global pharmaceutical and biotech sectors spent an estimated 280 billion USD on R\u0026amp;D in 2024, and shifts in economic health directly influence private R\u0026amp;D budgets that drive demand for Takara Bio’s reagents and services.\u003c\/p\u003e\n\u003cp\u003eDuring downturns, firms often trim discovery programs—McKinsey noted potential cuts of 5–10% in R\u0026amp;D spend—reducing orders for high-end enzymes and kits.\u003c\/p\u003e\n\u003cp\u003eA strong economy boosts VC into biotech; global VC funding rose to about 60 billion USD in 2024, expanding Takara Bio’s addressable customer base of startups and translational labs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflation and Operational Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRising global inflation in 2024–25 pushed chemical and energy input prices up 8–12% year-on-year, increasing Takara Bio’s raw material costs for enzymes and reagents and compressing gross margins reported at 22% in FY2024. Takara must balance higher production costs with competitive pricing for consumables in markets where price elasticity is high. The company’s ability to pass through price increases—observed partial pass-through of 60–70% in 2024—will determine its economic resilience and market-share retention.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rate Environments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHigher global interest rates raised borrowing costs, with Japan's 10-year JGB yield rising to ~0.7% in 2024 and US 10-year at ~4.5%, increasing capital costs for Takara Bio's planned cell and gene therapy plants.\u003c\/p\u003e\n\u003cp\u003eElevated rates constrain small biotech clients—VC funding into US biotech fell 46% in 2024—reducing outsourcing demand and pressuring Takara's sales.\u003c\/p\u003e\n\u003cp\u003eTakara Bio's debt servicing and investment returns are sensitive to BOJ and Fed policy shifts, affecting cash allocation for R\u0026amp;D and capacity expansion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigher yields raise capex financing costs for new facilities\u003c\/li\u003e\n\u003cli\u003eVC funding decline (−46% in 2024) reduces client demand\u003c\/li\u003e\n\u003cli\u003eMonetary policy shifts affect debt servicing and investment returns\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmerging Market Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpeconomic development in southeast asia and india where biotech r spending grew cagr diagnostics market expected to reach by offers takara bio routes diversify revenue via localized reagents instruments aligned rising clinical testing volumes.\u003e\n\u003cptailoring pricing local partnerships and cost-effective product lines to match lower per-capita healthcare spend gdp per capita in is vital capture expanding market segments sustain margin growth.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegion CAGR: ~8–10% (biotech R\u0026amp;D 2021–25)\u003c\/li\u003e\n\u003cli\u003eDiagnostics market SEA+India: est. $25–30B by 2026\u003c\/li\u003e\n\u003cli\u003eIndia GDP per capita 2024: ~$2,500\u003c\/li\u003e\n\u003cli\u003eStrategy: localized pricing, partnerships, cost-focused SKUs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/ptailoring\u003e\u003c\/peconomic\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFY24: ¥1.8B FX gain, 22% margin; VC down, global biotech R\u0026amp;D $280B\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFY2024: FX gains ¥1.8B; Yen −15% vs USD since 2021; gross margin 22%; partial price pass-through 60–70%; VC funding down 46% (US 2024); global biotech R\u0026amp;D ~$280B (2024); global VC ~$60B (2024); input costs +8–12% (2024–25); JGB 10y ~0.7%, US 10y ~4.5%; SEA\/India biotech R\u0026amp;D CAGR ~8–10% (2021–25).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX gains\u003c\/td\u003e\n\u003ctd\u003e¥1.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVC global\u003c\/td\u003e\n\u003ctd\u003e$60B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$280B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eTakara Bio PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Takara Bio PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategy or investment review.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751889383801,"sku":"takara-bio-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/takara-bio-pestle-analysis.png?v=1772235813","url":"https:\/\/matrixbcg.com\/products\/takara-bio-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}